## **A Novel Method of Highly Enantioselective Synthesis of y\_Hydroxy-P-Keto Phosphonates** *via* **Allene Oxides**

**Marek M. Kabat#** 

Institute of Organic Chemistry, Polish Academy of Sciences, Kasprzaka 44,01-224 Warszawa, Poland

Abstract: Optically active y-hydroxy-*β-keto phosphonates 8 (96-97% ee)* were obtained starting from 1*trimethylsilyl-I-alkynes 1 by employing chiral allene oxides for introduction of a-hydroxy carbonyl functionaliry.* 

8-Keto phosphonates are commonly employed as synthetic reagents, particularly in the Horner-Wadsworth-Emmonds reaction.<sup>1)</sup> The commonly used methods for preparing  $\beta$ -keto phosphonates are the Arbuzov reaction<sup>2)</sup> and acylation of phosphonate anions<sup>3)</sup>. Both methods suffer from individual restrictions and have common limitations. The Arbuzov reaction of trialkyl phosphites and  $\alpha$ -halo ketones is limited to the highly reactive  $\alpha$ -halo ketones, due to poor nucleophilicity of phosphites and the Perkow reaction<sup>4</sup>) to give enol phosphates. The acylation of alkyl phosphate anions suffers from the limited availability of alkyl phosphonates and low reactivities resulting from the proton exchange between the usually more acidic  $\beta$ -keto phosphonates generated and the 1-lithio alkyl phosphonates used as starting materials. In contrast to the significant progress<sup>5)</sup> that has expanded the original scope of the Horner-Wadsworth-Emmons condensation, relatively little work has appeared<sup>6)</sup> on new syntheses of  $\beta$ -keto phosphonates.

In connection with our work<sup>7)</sup> on the application of chiral allene oxides for the synthesis of  $\alpha$ substituted carbonyl compounds, we would like to report a highly enantioselective, mild method for the preparation of  $\gamma$ -hydroxy-β-keto phosphonates (96-97% ee) by using allene oxide methodology<sup>8)</sup> for introduction of the  $\alpha$ -hydroxy carbonyl functionality.

The starting compounds, I-trimethylsilyl-l-acetylenes **1, (cf.** the Scheme) were transformed into  $(2S,3S)$ -epoxy-aldehydes 4 in a three step protocol:<sup>9</sup>) i) hydromagnesiation<sup>10</sup> of 1 and reaction with formaldehyde to form (E)-allylic alcohols 2 ii) Sharpless asymmetric epoxidation<sup>11)</sup> [<sup>t</sup>BuOOH and L-(+)diethyl tartrate/Ti(O<sup>i</sup>Pr)<sub>4</sub>] followed by iii) PCC oxidation of 3. The optical purity of the epoxides 3 (97% ee) was established by their transformation into MTPA esters. Aldehydes 4 were subsequently reacted with dialkyl phosphites (R'O)<sub>2</sub>P(O)H (R'=Me, Et) in the presence <sup>12</sup>) of DBU in THF solution giving a mixture of diastereomeric alcohols  $5$  which subsequently were transformed into mesylates 6. Compounds 6 were prepared with the aim to serve as allene oxides precursors for a fluoride promoted elimination process. Thus, treatment of a THF solution of 6 at room temperature with 1 eq of TBAF and 10 eq of  $H_2O$  provided allene oxides 7 which could be opened by water *in situ* to yield the required  $(R)$ - $\gamma$ -hydroxy- $\beta$ -keto phosphonates  $8^{13}$ ). The optical purity of the phosphonates 8 (96-97% ee by <sup>1</sup>H NMR with Eu(hfc)<sub>3</sub> of 8 protected with  $t$ BuMe<sub>2</sub>SiCl) was demonstrated to be the same as silyl epoxides 3.

By application of the method described above various  $(R)$ - or  $(S)$ -  $\gamma$ -hydroxy- $\beta$ -keto phosphonates (depending on the chiral catalyst used for the Sharpless epoxidation) may be obtained for further transformation into the desired chiral products.



## **REFERENCESAND NOTES**

# Present address: Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, NJ 07110, USA.

1) a) W. S. Wadsworth Jr., *Org. React.,* 25, 73 (1977), b) B. J. Walker; *Organophosphorus Reagents in Organic Synhesis,* J. I. G. Cadogan Ed., Academic Press: New York, 1974, pp 155-206;

2) B. A. Arbuzov, *Pure Appl. Chem.,* 9, 307 (1964);

3) M. Mikolajczyk and P. Bialczewski, *Synthesis,* 1984, 691;

4) W. Perkow, K. Ullerich, and F. Meyer, *Naturwissenschaften,* 39, 353 (1952);

5) Recent examples: a) W. C. Still and C. Gennari, *Tetrahedron Lett.,* 24, 4405 (1983); b) P. Sampson, G. B. Hammond and D. F. Wiemer, *J. Org. Chem.,* 51, 4342 (1986); c) M. A. Blanchette, W. Choy, J. T. Dawid, A. P. Essenfeld, S. Masamune, W. R. Rough, and T. Sakai, *Tetrahedron* Lett., 25, 2183 (1984);

6) Recent examples: a) Y. J. Koh and D. Y. Oh, *Tetrahedron Lett.,* 34, 2147 (1993); b) K Lee and D. F. Wiemer, *J. Org. Chem.,* 56 5556 (1991); c) S. Hong, K. Chang, B. Ku, and D. Y. Oh, *Tetrahedron Lett.,* 30, 3307 (1989); d) B. E. Maryanoff and A. B. Reitz, *Chem. Rev.,* 89, 863 (1989);

7) M. M. Kabat, *Tetrahedron: Asymm.,* 4, 1417 (1993);

8) T. H. Chan and B. S. Ong, *J. Org. Chem.,* 43, 2995 (1978);

9) Y. Takeda, T. Matsumoto, and F. Sato, *J. Org. Chem.,* 51, 4728 (1986);

10) F. Sato, H. Ishikawa, and M. Sato, *Tetrahedron Lett,* 22, 85 (1981);

11) a) T. Katsuki and K. B. Sharpless, *J. Am. Chem. Soc.,* 102, 5974 (1980); b) Y. Gao, R. M. Hansen, J. M. Klunder, S. Y. Ko, H. Masamune, and K. B. Sharpless, *J. Am. Chem. Soc.,* 109, 5765 (1987);

12). For example: F. Hammerschmidt, *Liebigs Ann. Chem.,* 1991, 469; for applying other bases see: F. Texier-Boullet and M. Lequitte, *Tetrahedron Lett.,* 27, 3515 (1986) and references cited therein;

13) Experiments were carried out in 1 mmol scale. Analytical data for 8 (R=n-C<sub>4</sub>H<sub>9</sub>, R'=C<sub>2</sub>H<sub>5</sub>); b.p.=140-142 °C/0.4 mmHg (Kugelrohr);  $[\alpha]_D^{20}= +11.1$  ° (c 0.6, CH<sub>2</sub>Cl<sub>2</sub>); IR (CHCl<sub>3</sub>): 3408 (OH), 1715 (C=O) and 1027 [P(OEt)<sub>2</sub>] cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>): 0.91 (3H, t, J 7.5, CH<sub>3</sub>), 1.34 (3H, t, J 7.0, OCH<sub>2</sub>CH<sub>3</sub>), 1.35 (3H, t, J 7.0, OCH<sub>2</sub>CH<sub>3</sub>), 1.3-1.45 (4H, m, CH<sub>2</sub>), 1.53-1.65 (1H, m, CH<sub>2</sub>), 1.75-1.85 (1H, m, CH<sub>2</sub>), 3.21 and 3.37  $(2H, dqAB, J_{AB} 13.1, J_{PH} 23.2, CH_2-P), 4.1-4.25$  (5H, m, OCH<sub>2</sub>- and CH-OH); <sup>31</sup>P (CDC13): 20.47 (triplet of quintet,  $J$  23 and 7.5); <sup>13</sup>C (CDCI<sub>3</sub>): 13.93, 16.38 (d,  $J_{CP}$  8.4), 22.46, 27.25, 33.22, 38.67 (d,  $J_{CP}$  26.3), 63.10 (d, JCP 6.6), 77.49; MS: 267 (M+I, 1%), 238 (1), 221 (1), 209 (2), 179 (8), 152 (100), 125 (92), 108  $(28)$ , 97 (35); MS-HR: C<sub>11</sub>H<sub>23</sub>O<sub>5</sub>P requires 266.1283, found 266.1305.

(Received in UK 21 September 1993; accepted 22 October 1993)